Nkarta advances NKX019 into second dose cohort; cash runway into 2029

Nkarta, Inc.

Enrollment in second dose-escalation cohort of NKX019 for autoimmune diseases is underway.
Lymphodepletion with fludarabine+cyclophosphamide shows deep B-cell depletion in all patients vs. partial with cyclophosphamide alone.
Cash, cash equivalents, and investments of $316.5M as of Sept 30, 2025, expected to fund operations into 2029.
Net loss of $21.7M ($0.29 per share) for Q3 2025; R&D expenses $20.2M.
Preliminary data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.